35.1: Urinary Anti-infectives

Pharmacology for Nurses · LibreTexts

0%

Contents

    Text

    Size
    100%
    Theme
    Typeface
    Line length
    Spacing

    From LibreTexts, under CC BY 4.0, as the source states it; its equations are written in TeX, which the PDF shows typeset. This page at LibreTexts.

    35.1: Urinary Anti-infectives
    Learning Objectives

    By the end of this section, you should be able to:

    • 35.1.1 Identify the characteristics of urinary anti-infective drugs used for urinary and bladder disorders.
    • 35.1.2 Explain the indications, actions, adverse reactions, contraindications, and interactions of urinary anti-infective drugs used for urinary and bladder disorders.
    • 35.1.3 Describe nursing implications of urinary anti-infective drugs used for urinary and bladder disorders.
    • 35.1.4 Explain the client education related to urinary anti-infective drugs used for urinary and bladder disorders.

    Urinary anti-infectives are a class of drugs specifically used to treat infections of the urinary tract, including the bladder, urethra, ureters, and kidneys (Figure 35.2). They are designed to target and eliminate the bacteria or other microorganisms causing urinary infection.

    A diagram shows the structures of the human urinary system that are present in both males and females. The adrenal gland is above the kidneys. The renal artery and renal vein enter each kidney to move blood through the kidneys or back to the heart. The ureter goes from the kidneys to the urinary bladder. The urinary bladder narrows as it descends into the urethra.
    Table 35.1 Drug Emphasis Table: Urinary Anti-infectives (source: https://dailymed.nlm.nih.gov/dailymed/)

    Adverse Effects and Contraindications

    Common adverse effects of urinary anti-infectives include nausea, vomiting, abdominal pain, anorexia, rash, headache, photosensitivity, and dizziness. Serious adverse effects can occur with certain urinary anti-infectives, including exfoliative dermatitis, Stevens–Johnson syndrome, and fulminant hepatic necrosis.

    Contraindications include renal and hepatic insufficiency and hypersensitivity to the drug or any of its components. Certain urinary anti-infectives are contraindicated in clients with blood dyscrasias and in specific pediatric populations.

    Table 35.2 is a drug prototype table for urinary anti-infectives featuring TMP/SMX. It lists drug class, mechanism of action, adult dosage, indications, therapeutic effects, drug and food interactions, adverse effects, and contraindications.

    Drug Class
    Anti-infective

    Mechanism of Action
    Inhibits the bacterial synthesis of tetrahydrofolic acid, which is necessary in the synthesis of thymidine, purines, and bacterial DNA
    Drug Dosage
    Regular-strength tablet: one 400 mg/80 mg tablet orally twice daily.
    Double-strength tablet: one 800 mg/160 mg tablet orally twice daily.
    Indications
    Treatment of UTIs due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris

    Therapeutic Effects
    Elimination of bacteria that cause UTIs
    Drug Interactions
    Dofetilide
    Warfarin
    Nonsteroidal anti-inflammatory drugs
    Phenytoin
    Methotrexate
    Cyclosporine
    Digoxin
    Amantadine

    Food Interactions
    No significant interactions
    Adverse Effects
    Nausea, vomiting, anorexia
    Rash, urticaria
    Severe cutaneous reactions
    Fulminant hepatic necrosis
    Blood dyscrasias
    Photosensitivity
    Hyperkalemia
    Contraindications
    Hypersensitivity
    History of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulfonamides
    Megaloblastic anemia due to folate deficiency
    Infants younger than 2 months of age
    Severe renal or hepatic insufficiency

    Caution:
    May cause Clostridioides difficile–associated diarrhea
    Table 35.2 Drug Prototype Table: Trimethoprim and Sulfamethoxazole (TMP/SMX) (source: https://dailymed.nlm.nih.gov/dailymed/)

    Nursing Implications

    The nurse should do the following for clients who are taking urinary anti-infectives:

    • Before administering the drug, check the client’s medical history, current drug list, and allergies.
    • Before administering the drug, confirm the results of baseline laboratory tests, including, but not limited to, urinalysis, urine culture and sensitivity, complete blood cell count, and renal and hepatic function levels.
    • For clients receiving nitrofurantoin, monitor for acute and subacute signs of respiratory reactions, such as dyspnea, chest pain, chills, fever, and cough, and notify the health care provider if these develop.
    • For clients receiving TMP/SMX, monitor for early signs of blood dyscrasias, such as sore throat, fever, or pallor, and notify the health care provider if these develop.
    • Monitor intake, output, and urine specific gravity. Report significant decreases in urinary output to the health care provider.
    • Report any signs of superinfection, such as stomatitis, anogenital discharge, or itching, to the health care provider.
    • Provide client teaching regarding the drug and when to call the health care provider. See below for client teaching guidelines.

    Client Teaching Guidelines

    The client taking a urinary anti-infective should:

    • Increase their daily fluid intake (avoiding substances that cause diuresis, such as caffeine), if not contraindicated, to avoid the development of kidney stones.
    • Rinse their mouth out thoroughly after taking nitrofurantoin because this drug may stain the teeth.
    • Ask the health care provider before taking certain urinary anti-infectives, such as nitrofurantoin, if they are pregnant, are thinking of becoming pregnant, are breastfeeding, or are considering giving these medications to an infant younger than 1 month of age because they may cause serious adverse effects such as blood dyscrasias, anemia, and fetal abnormalities.
    • Avoid excessive exposure to sunlight when taking TMP/SMX because photosensitivity may occur, and sun exposure may cause sunburn or skin rash.

    The client taking a urinary anti-infective should not:

    • Crush tablets or open capsules unless directed by a pharmacist because these drugs may cause esophageal or stomach irritation.
    • Stop taking the drug unless directed by the health care provider. Drugs in this class help eliminate bacteria in the body and can result in a worsening infection if the drug course is stopped early. Stopping early may also contribute to antibiotic resistance.

    FDA Black Box Warning

    Urinary Anti-infectives

    Nitrofurantoin may cause acute, subacute, or chronic pulmonary reactions (such as diffuse interstitial pneumonitis or pulmonary fibrosis, or both). Monitoring for these conditions is warranted.

    Trimethoprim and sulfamethoxazole (TMP/SMX) may cause acute eosinophilic pneumonia, acute and delayed lung injury, interstitial lung disease, and acute respiratory failure resulting in prolonged mechanical ventilation, extracorporeal membrane oxygenation (ECMO), the need for lung transplantation, or death. Monitoring for these conditions is warranted.


    This page titled 35.1: Urinary Anti-infectives was last modified on Sun, 29 Dec 2024 08:29:08 GMT and is shared under a CC BY 4.0 license and was authored, remixed, and/or curated by OpenStax.